Pankhondo yolimbana ndi khansa ya kapamba, mayesero azachipatala atsopano komanso otsogola akhala ovuta kwambiri. Mayeserowa amapatsa odwala mwayi wopeza chithandizo chanthawi yayitali chomwe chingapangitse kuti kafukufuku apite patsogolo komanso kukhala ndi chiyembekezo chopeza zotsatira zabwino.
Chithandizo chilichonse chomwe chilipo masiku ano chidafufuzidwa, kupangidwa ndikuvomerezedwa kudzera mu mayeso azachipatala - kafukufuku wofufuza yemwe amafufuza zamankhwala atsopano kapena kuphatikiza kwamankhwala omwe alipo kuti adziwe ngati ali opindulitsa kwa anthu omwe ali ndi khansa ya kapamba. Khansara ya Pancreatic ikukula kwambiri padziko lonse lapansi, ikuyendetsa kufunikira kwazamankhwala azachipatala komanso kuyesa kupanga mankhwala. Zosowa zosakwanira zokhudzana ndi matendawa zikukopa makampani ambiri amitundu yosiyanasiyana kuti agwiritse ntchito malonda. Zinthu izi kuphatikiza kukwera kwa ndalama zothandizira zaumoyo padziko lonse lapansi zidzakulitsa kukula kwa msika. Lipoti lochokera ku Global Market Insight linanena kuti kukula kwa Pancreatic Cancer Treatment Market Market kukuyembekezeka kupanga ndalama zambiri kuyambira 2021 mpaka 2027. Lipotilo linapitiriza kuti: "Khansa ya kapamba imatengedwa kuti ndi imodzi mwa mitundu yoopsa kwambiri ya khansa yomwe imachokera m'matumbo a pancreatic ndipo imatha mofulumira. kufalikira ku ziwalo zapafupi. Zosankha zopanda thanzi monga kusuta, kumwa mowa ndi kusuta fodya komanso matenda okhudzana ndi moyo monga kunenepa kwambiri ndi matenda a shuga ndi zina mwa zomwe zimayambitsa khansa ya m'mimba. Bungwe la American Cancer Society linati anthu oposa 60,000 a ku America adzapezeka ndi khansa ya m’mapapo mu 2021. Zinthu ngati zimenezi zikuonekanso m’madera ena ambiri padziko lapansi ndipo zingathandize kuti makampani aziyenda bwino.” Makampani omwe akugwira ntchito pa biotech ndi pharma m'misika sabata ino akuphatikiza Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.
Global Market Insight inawonjezera kuti: "Chemotherapy, immunotherapy, chithandizo chomwe mukufuna, komanso chithandizo cha mahomoni, pakati pa ena, ndi mitundu yosiyanasiyana ya chithandizo cha khansa ya kapamba. Mwa izi, gawo lazachipatala lomwe likuyembekezeredwa likuyembekezeka kutenga gawo lalikulu pamsika pofika chaka cha 2027. Thandizo lomwe amalipiritsa limayang'ana mapuloteni enieni a khansa, majini, kapena minyewa yomwe imathandizira kukula kwa khansa. Chithandizocho chimalepheretsa kukula ndi kufalikira kwa maselo a khansa ndikuchepetsa kuwonongeka kwa omwe ali ndi thanzi. Thandizo lomwe akuyembekezeredwa liwona kufunikira kwa chithandizo cha khansa ya pancreatic m'zaka zikubwerazi. "
Oncolytics Biotech® Imapereka Zosintha Zabwino Zachitetezo pa Pancreatic Cancer Cohort ya Multi-Indication Phase 1/2 Mayesero a Khansa ya M'mimba - Oncolytics Biotech® ) lero yalengeza kumaliza bwino kwachitetezo chaodwala atatu chachitetezo cha gulu la khansa ya pancreatic ya Gawo 1/2 la kafukufuku wa GOBLET potsatira kuunika kochitidwa ndi Data Safety Monitoring Board (DSMB). A DSMB sanazindikire zachitetezo mwa odwalawa ndipo adalimbikitsa kuti phunzirolo lipitirire monga momwe adakonzera. Chitetezo cha gulu lachitatu la metastatic colorectal cancer chikupitilirabe.
Kafukufuku wa GOBLET akuyendetsedwa ndi AIO, gulu lotsogolera lazachipatala la oncology ku Germany, ndipo lapangidwa kuti liwunikire chitetezo ndi mphamvu ya pelareorep kuphatikiza ndi Roche's anti-PD-L1 checkpoint inhibitor atezolizumab mwa odwala metastatic pancreatic, metastatic. colorectal, komanso khansa yapamwamba yamatako. Kafukufukuyu akupitilirabe ndipo akuyembekezeka kulembetsa odwala m'malo 14 oyeserera azachipatala ku Germany.
Gulu la khansa yapancreatic ya GOBLET la kafukufuku wa GOBLET limakulitsa zidziwitso zamankhwala zomwe zidanenedwapo kale zomwe zikuwonetsa kuyanjana ndi zotsutsana ndi khansa ya pelareorep kuphatikiza ndi zoletsa zoletsa odwala khansa ya pancreatic omwe adapita patsogolo atalandira chithandizo chamzere woyamba (ulalo wa PR, ulalo ku positi). Zimamanganso pazidziwitso zam'mbuyomu zam'chipatala zomwe zidawonetsa kuwonjezeka kopitilira 80% kwa kupulumuka kwapakatikati kwa odwala khansa ya pancreatic omwe ali ndi mawu otsika a CEACAM6 omwe adalandira pelareorep kuphatikiza ndi chemotherapy (ulalo ku PR, ulalo ku positi). Kuphatikiza pa kuwunika chitetezo ndi mphamvu ya chithandizo cha pelareorep-atezolizumab, GOBLET ikufunanso kuwonetsa kuthekera kwa CEACAM6 ndi T cell clonality monga zolosera zam'tsogolo, zomwe zingapangitse mwayi wopambana maphunziro olembetsa mtsogolo mwa kulola kusankha odwala oyenera kwambiri. .
Seagen Inc. posachedwapa adalengeza deta kuchokera ku mayesero achipatala a gawo 1 ophatikiza SEA-CD40 ndi chemotherapy ndi anti-PD-1 mwa odwala omwe ali ndi metastatic PDAC pa msonkhano wapachaka wa ASCO GI womwe ukuchitikira ku San Francisco, January 20 - 22, 2022. SEA -CD40 ndi buku, kufufuza, nonfucosylated monoclonal receptor-agonistic antibody yopita ku CD40, yomwe imasonyezedwa pa maselo owonetsera antigen. M'mawonekedwe a preclinical, kuphatikiza kwa SEA-CD40 ndi chemotherapy kudapangitsa kuti pakhale antitumor ntchito yomwe imakulitsidwanso ndi mankhwala odana ndi PD-1.
M'mayesero omwe akupitilira 1, SEA-CD40 idaphatikizidwa ndi chemotherapy [gemcitabine ndi nab-paclitaxel (GnP)], ndi anti-PD-1 (pembrolizumab), mwa odwala 61 omwe ali ndi metastatic metastatic PDAC. Mwa awa, odwala 40 adalandira 10 mcg / kg ndipo odwala 21 adalandira 30 mcg / kg ya SEA-CD40. Mfundo zazikuluzikulu zikuphatikiza kuchuluka kwa mayankho otsimikizika (cORR) pa RECIST v1.1 ndi wofufuza, kupulumuka popanda kupita patsogolo (PFS) ndi kupulumuka konse (OS) "Zochita zoyambilira ndizolimbikitsa kutengera zotsatira zamankhwala am'mbuyomu. Kutsatiridwa kwina kukufunika kuti tidziwe zomwe tingachite pa khansa ya pancreatic, "atero a Roger Dansey, MD, Chief Medical Officer ku Seagen. "Tikupitiliza kuyesa kuyesa kwa gawo 2 kwa SEA-CD40 mu melanoma komanso khansa ya m'mapapo yomwe si yaying'ono."
Exact Sciences Corp. posachedwapa analengeza deta ntchito kwa m'badwo wachiwiri Cologuard (Mipikisano chandama chopondapo DNA) mayeso kusonyeza lonse tilinazo 95.2% kwa colorectal khansa (CRC) makamaka 92.4% kwa zitsanzo zoipa zotsimikiziridwa ndi colonoscopy. Kuwunika kwamagulu ang'onoang'ono kunawonetsa 83.3% kukhudzika kwa dysplasia yapamwamba kwambiri, zotupa zowopsa kwambiri, ndi 57.2% pazotupa zonse zapamwamba. Izi zidzaperekedwa Januware 22 ku ASCO GI pachithunzi chotchedwa, "Second-generation Multi-target Stool DNA Panel Imazindikira Khansa Yamtundu Wambiri ndi Zotupa Zapamwamba Kwambiri."
Cologuard ndiye mayeso oyamba komanso okhawo ovomerezeka ndi FDA, osasokoneza DNA omwe amagwiritsidwa ntchito kuyesa anthu omwe ali pachiwopsezo cha CRC. Exact Sciences ikupanga Cologuard ya m'badwo wachiwiri kuti iwonetsetse kutsimikizika kwazomwe zimayesedwa, kuchepetsa kuchuluka kwabodza komanso kukulitsa kuchuluka kwa zotupa za precancerous. Kafukufukuyu akuwonetsa kuthekera kwa gulu la tsankho kwambiri la zolembera za methylated DNA ndi fecal hemoglobin kuti akwaniritse zochitika zenizeni padziko lapansi. Ngati kuvomerezedwa, kuyezetsa kwa m'badwo wachiwiri wa Cologuard kumatha kuthandizira kuchulukirachulukira ndikutumiza anthu ochepa kuti atsatire ma colonoscopies mosafunikira ndikuzindikira omwe ali ndi khansa yapamwamba kwambiri asanayambe kudwala khansa, kuthandiza kupewa matendawa.
Bristol Myers Squibb posachedwapa adalengeza kuti Komiti Yopereka Mankhwala Othandizira Anthu (CHMP) ya European Medicines Agency (EMA) yalimbikitsa kuvomereza kwa Breyanzi (lisocabtagene maraleucel; liso-cel), CD19-directed chimeric antigen receptor (CAR) T cell. Thandizo lochiza odwala akuluakulu omwe adabwereranso kapena kukana (R/R) amafalitsa B-cell lymphoma (DLBCL), mediastinal yayikulu B-cell lymphoma (PMBCL), ndi follicular lymphoma grade 3B (FL3B) pambuyo pa mizere iwiri kapena kuposerapo. za systemic therapy. Malingaliro a CHMP tsopano awunikiridwanso ndi European Commission (EC), yomwe ili ndi mphamvu zovomereza mankhwala ku European Union (EU).
Kura Oncology, Inc., kampani yachipatala ya biopharmaceutical yomwe idadzipereka kuti ikwaniritse lonjezo lamankhwala olondola pochiza khansa, posachedwapa yalengeza kuti US Food and Drug Administration (FDA) yakweza gawo lachipatala pa KOMET-001 Phase. Phunziro la 1b la KO-539 kwa odwala omwe ali ndi vuto lobwereranso kapena refractory pachimake myeloid leukemia (AML). Kusamalidwako pang'ono kunathetsedwa potsatira kuvomerezana ndi a FDA pa njira yochepetsera ya Company of differentiation syndrome, chochitika chodziwika bwino chokhudzana ndi osiyanitsa othandizira pochiza AML.
